BioCryst (BCRX) AI Stock Analysis

• Market Cap: $2.16B
• Dividend Yield: N/A
• Average Volume (3M): 5.77M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.94
• Revenue Growth: 41.67%
• EPS Growth: 75.79%
• Country: US
• Employees: 580
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 209,250,270
• 10 Day Avg. Volume: 6,401,134
• 30 Day Avg. Volume: 5,773,369
• PEG Ratio: -0.99
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -38.96
• Enterprise Value/Market Cap: 0.82
• Enterprise Value/Revenue: 1.11
• Enterprise Value/Gross Profit: 4.04
• Enterprise Value/Ebitda: -10.59
• 1Y Price Target: $16.33
• Price Target Upside: 57.17% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12

• Rating: 66 Neutral
• Price Target: $11.00 ▲( 5.87% Upside)

BioCryst's strong technical momentum and positive earnings call drive the score higher, despite financial instability. Regulatory successes and strategic leadership changes also support the score, but persistent net losses and negative equity pose significant risks.

Positive Factors

Analyst Confidence

Analyst reiterates Buy with a new price objective of $13, reflecting confidence in the company's growth strategy.

Product Development

FDA granted a Priority Review and a PDUFA target action date to BCRX's NDA seeking approval of its pediatric formulation of Orladeyo for HAE patients aged 2-11 yrs, representing the first oral prophylactic therapy for this age group.

Revenue Growth

Biocryst raised its full year revenue guidance to $580-$600M due to unprecedented conversion of patients from free to paid therapy.

Negative Factors

Market Assumptions

The pediatric label expansion is viewed as a notable incremental opportunity given that it is not included in the current 2025 sales guidance, nor has been included in BCRX's assumptions for Orladeyo to attain $1B in global sales by 2029.

Market Perception

The recommendation to buy is based on a valuation that continues to underappreciate Orladeyo's strong growth prospects.

BioCryst Business Overview & Revenue Model

Company Description

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

How the Company Makes Money

BioCryst Pharmaceuticals makes money through the sale of its approved drug, Orladeyo, which is used to prevent attacks in patients with hereditary angioedema (HAE). Revenue is primarily generated from product sales and licensing agreements. The company enters into partnerships and collaborations to license its proprietary technology and compounds, providing additional revenue streams through upfront payments, milestone payments, and royalties. Furthermore, BioCryst invests in research and development to expand its pipeline of drug candidates, which may lead to future revenue opportunities upon successful development and commercialization.

BioCryst Financial Statement Overview

Summary

BioCryst shows strong revenue growth and gross margins but struggles with profitability and financial stability. The company's negative equity and high leverage are concerning, though improvements in operating cash flows provide a glimmer of hope. Continued efforts to manage costs and improve cash generation will be critical for future stability and growth.

Income Statement

BioCryst has exhibited significant revenue growth, with a 36% increase from 2023 to 2024, and a notable 110% growth since 2020. The gross profit margin is strong at approximately 97%, indicating effective cost management relative to revenue. However, the company remains unprofitable, with a negative net profit margin of -19.7% in 2024, although this is an improvement from previous years. The negative EBIT and EBITDA margins indicate ongoing operational challenges.

Balance Sheet

The company has a concerning balance sheet with negative stockholders' equity, which suggests potential financial instability. Although the debt-to-equity ratio is not calculable due to negative equity, the high total liabilities relative to assets imply high leverage. The equity ratio of -97% in 2024 highlights this imbalance. These factors indicate potential risks related to solvency and financial flexibility.

Cash Flow

Operating cash flow has improved, reducing from -$95 million in 2023 to -$52 million in 2024. However, free cash flow remains negative, reflecting ongoing cash burn. The free cash flow to net income ratio and operating cash flow to net income ratio are both negative, indicating that cash generation remains a challenge. Despite these issues, the company has managed to grow its free cash flow by 46% year-over-year.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
450.71M	331.41M	270.83M	157.17M	17.81M
	Gross Profit
438.44M	326.75M	264.23M	149.91M	16.14M
	EBIT
-2.54M	-103.71M	-148.44M	-177.72M	-174.76M
	EBITDA
12.81M	-116.33M	-143.85M	-121.74M	-167.56M
	Net Income Common Stockholders
-88.88M	-226.54M	-247.12M	-184.06M	-196.57M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
320.85M	388.99M	442.39M	514.43M	300.37M
	Total Assets
490.42M	516.96M	550.00M	588.15M	334.71M
	Total Debt
808.74M	848.71M	741.45M	593.24M	124.72M
	Net Debt
704.03M	714.50M	436.69M	88.85M	-147.41M
	Total Liabilities
966.35M	972.49M	844.60M	695.14M	353.98M
	Stockholders Equity
-475.93M	-455.53M	-1.45B	-1.21B	-1.02B
Cash Flow		Free Cash Flow
-53.14M	-97.31M	-163.20M	-144.54M	-137.73M
	Operating Cash Flow
-52.02M	-95.14M	-161.85M	-142.16M	-137.22M
	Investing Cash Flow
52.59M	-131.50M	-128.24M	15.80M	-6.86M
	Financing Cash Flow
-5.76M	32.48M	88.03M	359.67M	302.70M

BioCryst Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.39
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCRX, the sentiment is Positive. The current price of 10.39 is above the 20-day moving average (MA) of 9.74, above the 50-day MA of 8.37, and above the 200-day MA of 7.98, indicating a bullish trend. The MACD of 0.60 indicates Positive momentum. The RSI at 63.96 is Neutral, neither overbought nor oversold. The STOCH value of 65.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BCRX.

BioCryst Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BCRX	66 Neutral	$2.16B	―	18.68%	―	41.67%	75.79%
MNKD	61 Neutral	$1.32B	41.83	-35.00%	―	32.50%	236.33%
KYMR	54 Neutral	$2.05B	―	-32.17%	―	-25.85%	-23.89%
AGIO	54 Neutral	$1.75B	2.67	60.26%	―	25.96%	―
Sector *	53 Neutral	$5.14B	3.06	-43.57%	2.81%	16.81%	-0.12%
ARWR	50 Neutral	$2.25B	―	-24.67%	―	1436.97%	68.03%
IRON	43 Neutral	$1.66B	―	-23.34%	―	―	-14.19%

BioCryst Corporate Events

BioCryst’s ORLADEYO Receives FDA Priority Review

On May 14, 2025, BioCryst Pharmaceuticals announced that the FDA accepted its new drug application for ORLADEYO® oral granules for pediatric patients with hereditary angioedema aged 2 to 11 years, granting it priority review with a target action date of September 12, 2025. If approved, ORLADEYO would be the first targeted oral prophylactic therapy for this age group, potentially improving disease management and reducing acute attacks, with additional regulatory filings planned in Europe, Japan, and Canada.

The most recent analyst rating on (BCRX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.

BioCryst Reports Strong Q1 2025 Financial Performance

BioCryst Pharmaceuticals reported a strong financial performance for the first quarter of 2025, with ORLADEYO net revenue reaching $134.2 million, a 51% increase year-over-year. The company has increased its full-year revenue guidance for ORLADEYO to between $580 million and $600 million and expects to achieve profitability a year ahead of schedule. BioCryst is also advancing its pipeline with a new drug application for ORLADEYO oral granules for children with HAE and clinical trials for treatments targeting Netherton syndrome and diabetic macular edema. The company paid down $75 million of debt, saving approximately $23.5 million over the life of the loan, and plans to continue investing in its pipeline while maintaining financial growth.

BioCryst Expands Board with New Director Appointment

On April 30, 2025, BioCryst Pharmaceuticals announced the expansion of its Board of Directors from ten to eleven members, with the election of Steven Frank, effective May 2, 2025. Mr. Frank, a respected healthcare investment banker, is expected to bring valuable expertise to the board as BioCryst aims to build on its commercial success and advance its pipeline. The appointment highlights BioCryst’s strategic focus on accelerating towards profitability and enhancing its position in the biopharma industry.

BioCryst Appoints CEO as Interim CFO Amid Transition

On February 28, 2025, BioCryst Pharmaceuticals announced the resignation of its Chief Financial Officer and Interim Principal Accounting Officer, Anthony Doyle, effective April 9, 2025. To ensure a smooth transition, Doyle will provide consulting services until May 31, 2025. Subsequently, on April 7, 2025, the company’s Board appointed CEO Jon P. Stonehouse as the Interim CFO and Interim Principal Accounting Officer. The company has also engaged a former biotechnology CFO as a consultant to assist during the transition while searching for a permanent CFO.

BioCryst CFO Anthony Doyle Resigns Effective April 2025

On February 28, 2025, BioCryst Pharmaceuticals announced the resignation of its Chief Financial Officer, Anthony Doyle, effective April 9, 2025. Doyle, who has been with the company since April 2020, played a crucial role during the global launch of ORLADEYO and in strengthening the company’s financial position as it nears profitability. His departure is not due to any disagreements with the company, and he will remain in his role until April 9 to ensure a smooth transition. The company has initiated a search for a new CFO.

BioCryst Faces Patent Challenge Amidst Strong Growth

In January 2025, BioCryst received a notice from Annora Pharma, challenging the patents of its drug ORLADEYO, with potential implications for its market exclusivity in the U.S. Despite this, BioCryst reported strong financial results for 2024, with significant revenue growth and an optimistic outlook for 2025. The company is expanding its pipeline with new clinical trials and aims to further increase ORLADEYO’s accessibility and market reach, particularly for pediatric patients with HAE.